# Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Study · id `cardio:ct-nct03080883` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03080883](<https://clinicaltrials.gov/study/NCT03080883>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03080883

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 370 participants.

## Technical summary

Registry record NCT03080883. Randomized; double masking; primary purpose prevention. Start 2017-07-14 (actual); primary completion 2022-06-07 (actual). Results posted on 2023-12-12.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 370 participants (enrolled count; ClinicalTrials.gov record NCT03080883, source copy `cardio:ctgov-nct03080883-2025-05-18`, retrieved 2026-10-31)
- Started: 2017-07-14 (actual) (ClinicalTrials.gov record NCT03080883, source copy `cardio:ctgov-nct03080883-2025-05-18`, retrieved 2026-10-31)
- Primary completion: 2022-06-07 (actual) (ClinicalTrials.gov record NCT03080883, source copy `cardio:ctgov-nct03080883-2025-05-18`, retrieved 2026-10-31)
- Completion: 2025-05-09 (actual) (ClinicalTrials.gov record NCT03080883, source copy `cardio:ctgov-nct03080883-2025-05-18`, retrieved 2026-10-31)
- Results first posted: 2023-12-12 (ClinicalTrials.gov record NCT03080883, source copy `cardio:ctgov-nct03080883-2025-05-18`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT03080883, source copy `cardio:ctgov-nct03080883-2025-05-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03080883-2025-05-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
- Condition: Cerebral Vein Thrombosis
- Condition: Deep Vein Thrombosis
- Condition: Hematopoietic and Lymphoid Cell Neoplasm
- Condition: Malignant Solid Neoplasm
- Condition: Metastatic Malignant Solid Neoplasm
- Condition: Pulmonary Embolism
- Condition: Splanchnic Vein Thrombosis
- Intervention (Drug): Apixaban
- Lead sponsor: Academic and Community Cancer Research United
- Lead sponsor class: OTHER
- Collaborator: National Cancer Institute (NCI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry lists this organization as a collaborator: National Cancer Institute (NCI) (`cardio:org-national-cancer-institute-nci`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial (`cardio:pubmed-38537780`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 66f22df3ebbee116580aab796a2265012d8a22a4f07c2f41700c7baabe2a544d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
